Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15698958 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL14709158 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL28489991 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL12280418 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL2362689 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL15859653 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL14709006 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL1509195 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL1255498 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL12910763 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46276-E1 | Triazolo(4,5-D)pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2017-01-17 | — | — | US | disclosed |
| EP-2707363-B1 | A PROCESS FOR THE PREPARATION OF BENZYL [(3AS,4R,6S,6AR)-6-HYDROXY-2,2- DIMETHYLTETRAHYDRO-3AH-CYCLOPENTA[D][1,3]DIOXOL]-4-YL]CARBAMATE AND INTERMEDIATES IN THE PROCESS | ASTRAZENECA AB (SE) | 2015-10-21 | — | — | EP | disclosed |
| US-9079873-B2 | Process for the preparation of benzyl [(3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol]-4-yl]carbamate and intermediates in the process | ASTRAZENECA AB (SE) | 2015-07-14 | — | — | US | disclosed |
| US-20150152111-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA UK LIMITED (GB) | 2015-06-04 | — | — | US | disclosed |
| US-20140296258-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON | ASTRAZENECA UK LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140135509-A1 | Process for the Preparation of Benzyl [(3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol]-4-yl]carbamate and Intermediates in the Process | ASTRAZENECA AB (SE) | 2014-05-15 | — | — | US | disclosed |
| US-20130109702-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA AB (GB) | 2013-05-02 | — | — | US | disclosed |
| US-8273879-B2 | Triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2012-09-25 | — | — | US | disclosed |
| US-20110218330-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
| EP-1386917-B1 | Intermediates for the preparation of certain triazolopyrimidines as P2T antagonists | ASTRAZENECA AB (SE) | 2011-06-22 | — | — | EP | disclosed |
| US-7250419-B2 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | ASTRAZENECA AB (SE) | 2007-07-31 | — | — | US | disclosed |
| US-7067663-B2 | Triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | disclosed |
| US-20060041132-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| EP-1135391-B1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1386921-A1 | Intermediates | AstraZeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1386917-A1 | Intermediates | AstraZeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| US-20030148888-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| US-6525060-B1 | P2T (P2YADP or P2TAC) receptor antagonists; anticoagulant, antithrombotic | ASTRAZENECA UK LIMITED (GB) | 2003-02-25 | — | — | US | disclosed |
| EP-1135391-A1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000034283-A1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148888-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | MGAM 4795/4885CA1 4866/4885CA2 4833/4885 |
| US-20150152111-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | MGAM 4597/4885CA1 4876/4885CA2 3132/4885 |
| US-20060041132-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | MGAM 4795/4885CA1 4866/4885CA2 4833/4885 |
| US-20140135509-A1 | Process for the Preparation of Benzyl [(3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol]-4-yl]carbamate and Intermediates in the Process | CYP4X1, CYP4B1, CBR3 | MGAM 2099/4885CA1 1334/4885CA2 832/4885 |
| US-20140296258-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON | GP6, THPO, P2RY6 | MGAM 3717/4885CA1 4870/4885CA2 2565/4885 |
| US-20130109702-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | MGAM 4597/4885CA1 4876/4885CA2 3132/4885 |
| US-20110218330-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | MGAM 4795/4885CA1 4866/4885CA2 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.